Quantum Cyber NV 2026年季度报告

FORM 10-Q (MARK ONE)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-41010 Quantum Cyber N.V.(Exact Name of Registrant as Specified in Its Charter) (Address of principal executive offices) +1 (203) 851-1599(Issuer’s telephone number) (Former name or former address, if changed since last report.)1501 Belvedere Road, Suite 500, West Palm Beach, Fl. 33406 Securities registered pursuant to Section 12(b) of the Act: None. Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements forthe past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☐No☒ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reportingcompany”, and “emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒As of August 13, 2026, 84,068,192 ordinary shares, nominal value €0.01 per share, were issued and outstanding. QUANTUM CYBER N.V. FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2026 TABLE OF CONTENTS PagePart I. Financial Information1Item 1.Financial Statements1Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations26Item 3.Quantitative and Qualitative Disclosures Regarding Market Risk33Item 4.Controls and Procedures33Part II. Other Information34Item 1.Legal Proceedings34Item1A.Risk Factors34Item 2.Unregistered Sales of Equity Securities and Use of Proceeds35Item 3.Defaults Upon Senior Securities35Item 4.Mine Safety Disclosures35Item 5.Other Information35Item 6.Exhibits37Signatures38 PART 1 – FINANCIAL INFORMATION Quantum Cyber N.V.(formerly Mainz Biomed N.V.)Condensed Consolidated Statements of Comprehensive Loss(Unaudited) Quantum Cyber N.V.(formerly Mainz Biomed N.V.)Condensed Consolidated Statements of Changes in Shareholders’ Equity(Unaudited) Quantum Cyber N.V.(formerly Mainz Biomed N.V.)Condensed Consolidated Statements of Cash Flows(Unaudited) Quantum Cyber N.V.(formerly Mainz Biomed N.V.)Notes to the Unaudited Condensed Consolidated Financial StatementsJune 30, 2026 NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Organization and Operations Quantum Cyber N.V. (the “Company”) is domiciled in the Netherlands. The Company’s registered office is at 200 Connecticut Ave.Suite 400, Norwalk, Connecticut. Prior to May 2026, substantially all of the Company’s operations were in Germany. The Company(f/k/a Mainz Biomed N.V.) was formed in 2021 to acquire the business of Mainz Biomed Germany GmbH. On April 22, 2026, theCompany’s shareholders approved change of its name, to Quantum Cyber N.V. In conjunction with the name change the Companychanged its Nasdaq ticker symbol to QUCY. Through February 2026, the Company was engaged in developing and selling in-vitro diagnostic (“IVD”) tests for the early detectionof cancer. The Company’s ColoAlert product was being marketed and sold in European markets and was developing its next-generation colorectal cancer screening product. During the six months ending June 30, 2026 the Board of the Company made thedecision to exit the colorectal cancer screening business and focus its effort on the development of its pancreatic cancer screeningproducts and to explore new business opportunities in the post-quantum cyber field. During the three months ended June 30, 2026 the Company’s Board made a decision to enter into its first business in line with itsexpansion strategy. The Company launched its business focused on an autonomous defense platform in May 2026 and in both Mayand June entered into two worldwide exclusive fully paid licenses to support a line of drone products. Further, in June the Companyentered into an agreement to acquire a plant and operating business to support the manufacture of those drones (the plant and companyacquisition closed in July 2026). NOTE